<DOC>
	<DOCNO>NCT01521377</DOCNO>
	<brief_summary>This randomize , placebo control , four period incomplete block , crossover thorough QT study estimate effect repeat dose GSK573719/GW642444M ( Vilanterol ) combination GSK573719 monotherapy QTc interval healthy male female subject compare placebo . At least 100 subject receive , four five possible , 10-day repeat dose treatment . Treatments placebo moxifloxacin placebo day 10 , placebo moxifloxacin ( 400mg ) day 10 , GSK573719/Vilanterol combination ( 125/25μg ) moxifloxacin placebo day 10 , GSK573719/Vilanterol combinatio ( 500/100μg ) moxifloxacin placebo day 10 , GSK573719 ( 500μg ) moxifloxacin placebo day 10 . All treatment double blind except moxifloxacin ( 400mg ) moxifloxacin placebo control , give single-blind single dose Day 10 appropriate treatment period . Primary endpoint individual time-matched change baseline QTcF GSK573719/Vilanterol combination ( 125/25μg ) GSK573719 ( 500μg ) , 0-24 hour dose Day 10 . Secondary endpoint include individual time-matched change baseline QTcF GSK573719/Vilanterol combination ( 500/100μg ) moxifloxacin ( 400mcg ) 0-24 hour dose Day 10 . Also change baseline QTci , QTcB , QT , QRS , RR , PR ventricular rate time point 10 day dose GSK573719 GSK573719/Vilanterol treatment single dose moxifloxacin ( 400mg ) . Maximal change baseline 0-24hours dosing day 10 derive QTcF , QTci QTcB treatment . Plasma concentration Day 10 ( 0-24 hour ) pharmacokinetic parameter GSK573719 Vilanterol also derive . Key assessment : 12- lead electrocardiogram ( ECG ) , pharmacokinetics . Safety assess blood pressure , heart rate , clinical laboratory safety test collection adverse event ( AEs ) .</brief_summary>
	<brief_title>QTc Study GSK573719+GW642444</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Male female 18 65 year age inclusive , time signing informed consent . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator believe find unlikely introduce additional risk factor interfere study procedure . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 MlU/ml estradiol &lt; 40 pg/ml ( &lt; 147 pmol/L ) confirmatory ] . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one contraception method Section 8.1 wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrollment . For form HRT , least 24 week elapse cessation therapy blood draw ; interval depend type dosage HRT . Following confirmation postmenopausal status , resume use HRT study without use contraceptive method . Childbearing potential agrees use one contraception method list Section 8.1 appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception Follow Up visit AST , ALT , alkaline phosphatase bilirubin ≤ 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Body weight ≥ 45 kg BMI within range 18 29.5 kg/m2 ( inclusive ) . Capable give write informed consent , include compliance requirement restriction list consent form . No significant abnormality 12lead ECG screening , include follow specific requirement : Ventricular rate ≥ 40 beat per minute PR interval ≤ 210msec Q wave &lt; 30msec ( 50 ms permit lead III ) QRS interval ≥ 60msec &lt; 120msec The waveform must enable QT interval clearly define QTcF interval must &lt; 450msec ( machine manual reading ) . A 24 hour Holter ECG screen demonstrates clinically significant abnormality find could interfere interpretation study result , assess appropriately train experienced reviewer Subjects able use Novel DPIsatisfactorily . Capable give write informed consent sign date write informed consent obtain , include compliance requirement restriction list consent form . Normal spirometry ( FEV1 ≥ 80 % predict , FEV1/FVC ≥ 70 % ) . Nonsmokers ( never smoke smoking &gt; 6 month &lt; 10 pack year history ( Pack year = ( cigarette per day smoked/20 ) x number year smoke ) ) . Available complete study . History presence medically significant disease , disorder would introduce additional risk interfere study procedure outcome . In particular , family history QT prolongation , early sudden cardiac death early cardiovascular disease . History symptomatic arrhythmia . A supine blood pressure persistently high 140/90 millimetre mercury ( mmHG ) screening . A supine mean heart rate outside range 4090 beat per minute ( BPM ) screening . History tendon disease/disorder relate quinolone treatment . History sensitivity study medication , include moxifloxacin , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . In particular , subject know allergy hypersensitivity quinolones , ipratropium bromide , tiotropium , atropine derivative . Or adverse reaction include immediate delay hypersensitivity β2 agonist sympathomimetic drug , Severe Milk Protein allergy A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . A positive prestudy drug/alcohol screen . A positive test HIV antibody . History regular alcohol consumption within 6 month study define : average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 8 g alcohol : halfpint ( ~240 ml ) beer , 1 glass ( 125ml ) wine 1 ( 25 ml ) measure spirit . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 3 month , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . Consumption seville orange , pummelo ( member grapefruit family ) grapefruit juice 7 day prior first dose study medication . Where participation study would result donation blood blood product excess 500 mL within 3 month period . Pregnant female determine positive serum βHCG test screening serum/ urine βHCG prior dose . Lactating female . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate . Urinary cotinine level indicative smoke history regular use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>LAMA</keyword>
	<keyword>Respiratory</keyword>
	<keyword>COPD</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Beta-2 Agonist</keyword>
	<keyword>Safety</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>LABA</keyword>
	<keyword>Muscarinic Receptor Agonist</keyword>
	<keyword>Healthy subject</keyword>
	<keyword>Moxifloxacin</keyword>
	<keyword>Anticholinergic</keyword>
	<keyword>GW642444</keyword>
	<keyword>GSK573719</keyword>
	<keyword>QTc</keyword>
</DOC>